희귀의약품 시장 규모, 점유율, 성장률 및 시장 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of orphan drugs Market

The global orphan drugs market is witnessing robust growth due to increasing awareness of rare diseases and strong regulatory support. The market was valued at USD 210.26 billion in 2025 and is projected to grow to USD 234.17 billion in 2026, reaching USD 603.89 billion by 2034, registering a CAGR of 12.57% during 2026-2034.

North America dominated the global market with a 54.04% share in 2025, driven by advanced healthcare infrastructure, favorable reimbursement policies, and strong research investments. The U.S. market alone is expected to reach USD 237.39 billion by 2032, supported by government incentives such as tax credits and market exclusivity for orphan drugs.

Market Trends

One of the key trends shaping the orphan drugs market is the rise in innovative product launches targeting rare diseases. Pharmaceutical companies are increasingly investing in targeted therapies such as biologics and gene therapies.

Additionally, blockbuster orphan drugs are gaining prominence. According to industry estimates, the top orphan drugs are expected to generate multi-billion-dollar revenues by 2026. The growing focus on precision medicine and immunotherapies is also transforming the treatment landscape for rare diseases.

Market Growth Drivers

1. Increasing R&D Investments

The rising investment in research and development is a major factor driving market growth. Pharmaceutical companies are focusing on developing novel therapies due to the high success potential in rare disease treatments.

Government initiatives are also supporting innovation. For example, policies promoting pharmaceutical R&D and innovation, especially in emerging markets, are accelerating drug development pipelines.

2. Growing Prevalence of Rare Diseases

The increasing number of rare disease patients globally is significantly boosting demand for orphan drugs. It is estimated that 300 million people worldwide are affected by rare diseases, with millions lacking effective treatment options.

This growing patient pool is encouraging companies to invest in advanced therapies and expand their product portfolios.

3. Favorable Regulatory Support

Supportive frameworks such as orphan drug designation, fast-track approvals, and financial incentives are encouraging companies to develop rare disease treatments. These policies reduce development risks and improve profitability.

Market Restraints

Despite strong growth potential, the market faces challenges due to the high cost of orphan drugs. Some therapies cost millions per treatment, limiting accessibility, especially in developing countries.

Additionally, limited reimbursement coverage and high out-of-pocket expenses restrict adoption, thereby impacting overall market growth.

Segmentation Analysis

By Therapy Area

• Oncology dominates the market with a 47.42% share in 2026, driven by increasing cancer-related orphan drug approvals.
• Hematology and neurology segments are also growing due to ongoing innovations and clinical advancements.
• Immunotherapy is expected to witness strong growth due to rising demand for immune-modulating treatments.

By Drug Type

• Biologics hold the largest share (74.44% in 2026) due to their effectiveness in treating complex rare diseases.
• Non-biologics account for a smaller share but continue to play a role in treatment options.

By Distribution Channel

• Hospital pharmacies dominate with 46.42% share in 2026, as many treatments require clinical supervision.
• Online pharmacies are emerging rapidly due to convenience and increased digital adoption.

Regional Insights

North America

North America leads the market, valued at USD 113.64 billion in 2025 and projected to reach USD 126.67 billion in 2026. The dominance is attributed to strong R&D capabilities and high disease awareness.

Europe

Europe accounted for USD 53.94 billion in 2025 and is expected to reach USD 59.93 billion in 2026, supported by regulatory initiatives and a large patient population.

Asia Pacific

The region is growing rapidly, with a market size of USD 35.76 billion in 2025, rising to USD 40.08 billion in 2026, driven by increasing healthcare spending and awareness.

Rest of the World

Regions such as Latin America and the Middle East & Africa are witnessing gradual growth due to improving healthcare access but remain underpenetrated.

Key Companies

Major players in the orphan drugs market include:

• Amgen Inc.
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca
• Novo Nordisk A/S

These companies focus on strategic collaborations, acquisitions, and pipeline expansion to strengthen their market position.

Industry Developments

Recent developments include partnerships, acquisitions, and regulatory approvals aimed at accelerating drug development. Companies are increasingly collaborating to bring innovative therapies to market faster and improve patient access globally.

Conclusion

The orphan drugs market is set for significant long-term growth, expanding from USD 210.26 billion in 2025 to USD 603.89 billion by 2034. Strong R&D investments, supportive government policies, and a growing rare disease population are key growth drivers.

However, high treatment costs remain a critical challenge that needs to be addressed to ensure wider accessibility. Overall, with continuous innovation and regulatory support, the market is expected to play a crucial role in transforming rare disease treatment worldwide.

Segmentation By Therapy Type

• Oncology
• Hematology
• Neurology
• Endocrinology
• Cardiovascular
• Respiratory
• Immunotherapy
• Infectious Diseases
• Others

By Drug Type

• Biologics
• Non-biologics

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region

• North America (By Therapy Type, By Drug Type, By Distribution Channel, By Country)
  • U.S.
  • Canada
• Europe (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of the World (By Therapy Type, By Drug Type, By Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Rare Diseases, By Key Countries/Regions, 2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. New Product Launches
• 4.4. Key Industry Developments: Mergers, Acquisitions & Partnerships
• 4.5. Technological Developments
• 4.6. Impact of COVID-19 on the Global Orphan Drugs Market

5. Global Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Therapy Area
  • 5.1.1. Oncology
  • 5.1.2. Hematology
  • 5.1.3. Neurology
  • 5.1.4. Endocrinology
  • 5.1.5. Cardiovascular
  • 5.1.6. Respiratory
  • 5.1.7. Immunotherapy
  • 5.1.8. Infectious Diseases
  • 5.1.9. Others
• 5.2. Market Analysis, Insights and Forecast - By Drug Type
  • 5.2.1. Biologics
  • 5.2.2. Non-Biologics
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies
  • 5.3.3. Online Pharmacies
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Therapy Area
  • 6.1.1. Oncology
  • 6.1.2. Hematology
  • 6.1.3. Neurology
  • 6.1.4. Endocrinology
  • 6.1.5. Cardiovascular
  • 6.1.6. Respiratory
  • 6.1.7. Immunotherapy
  • 6.1.8. Infectious Diseases
  • 6.1.9. Others
• 6.2. Market Analysis, Insights and Forecast - By Drug Type
  • 6.2.1. Biologics
  • 6.2.2. Non-Biologics
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies
  • 6.3.3. Online Pharmacies
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Therapy Area
  • 7.1.1. Oncology
  • 7.1.2. Hematology
  • 7.1.3. Neurology
  • 7.1.4. Endocrinology
  • 7.1.5. Cardiovascular
  • 7.1.6. Respiratory
  • 7.1.7. Immunotherapy
  • 7.1.8. Infectious Diseases
  • 7.1.9. Others
• 7.2. Market Analysis, Insights and Forecast - By Drug Type
  • 7.2.1. Biologics
  • 7.2.2. Non-Biologics
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Therapy Area
  • 8.1.1. Oncology
  • 8.1.2. Hematology
  • 8.1.3. Neurology
  • 8.1.4. Endocrinology
  • 8.1.5. Cardiovascular
  • 8.1.6. Respiratory
  • 8.1.7. Immunotherapy
  • 8.1.8. Infectious Diseases
  • 8.1.9. Others
• 8.2. Market Analysis, Insights and Forecast - By Drug Type
  • 8.2.1. Biologics
  • 8.2.2. Non-Biologics
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World Orphan Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Therapy Area
  • 9.1.1. Oncology
  • 9.1.2. Hematology
  • 9.1.3. Neurology
  • 9.1.4. Endocrinology
  • 9.1.5. Cardiovascular
  • 9.1.6. Respiratory
  • 9.1.7. Immunotherapy
  • 9.1.8. Infectious Diseases
  • 9.1.9. Others
• 9.2. Market Analysis, Insights and Forecast - By Drug Type
  • 9.2.1. Biologics
  • 9.2.2. Non-Biologics
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
  • 9.3.4. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Amgen Inc. (U.S.)
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & Services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Bayer AG (Germany)
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & Services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. F. Hoffmann-La Roche Ltd (Switzerland)
    • 10.2.3.1. Overview
    • 10.2.3.2. Products & Services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Alexion Pharmaceuticals Inc. (U.S.)
    • 10.2.4.1. Overview
    • 10.2.4.2. Products & Services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Novo Nordisk A/S (Denmark)
    • 10.2.5.1. Overview
    • 10.2.5.2. Products & Services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Novartis AG (Switzerland)
    • 10.2.6.1. Overview
    • 10.2.6.2. Products & Services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Bristol-Myers Squibb Company (U.S.)
    • 10.2.7.1. Overview
    • 10.2.7.2. Products & Services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. AstraZeneca (U.K.)
    • 10.2.8.1. Overview
    • 10.2.8.2. Products & Services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. DAIICHI SANKYO COMPANY, LIMITED (Japan)
    • 10.2.9.1. Overview
    • 10.2.9.2. Products & Services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)
  • 10.2.10. GlaxoSmithKline plc (U.K.)
    • 10.2.10.1. Overview
    • 10.2.10.2. Products & Services
    • 10.2.10.3. SWOT Analysis
    • 10.2.10.4. Recent Developments
    • 10.2.10.5. Strategies
    • 10.2.10.6. Financials (Based on Availability)